Latanoprost
| Code | Size | Price |
|---|
| CDX-L0069-M010 | 10 mg | £230.00 |
Quantity:
| CDX-L0069-M025 | 25 mg | £450.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
Short Term: +4°C, Long Term: -20°C
Documents
Further Information
Alternate Names/Synonyms:
Xalatan; Isopropyl (5Z,9a,11a,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate; 17-phenyl-13,14-dihydro trinor Prostaglandin F2alpha isopropyl ester
Appearance:
Yellowish oily liquid.
CAS:
130209-82-4
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Protect from light and moisture.
InChi:
InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1
InChiKey:
GGXICVAJURFBLW-CEYXHVGTSA-N
Long Description:
Chemical. CAS: 130209-82-4. Formula: C26H40O5. MW: 432.59. Latanoprost is the isopropyl ester of 17-phenyl-13,14-dihydro prostaglandin F2alpha (17-phenyl-13,14-dihydro PGF2alpha). It is a prodrug form of the free acid, which is a potent agonist of the FP prostaglandin receptor in the eye. Latanoprost reduces intraocular pressure in glaucoma patients with few side effects.
MDL:
MFCD00216074
Molecular Formula:
C26H40O5
Molecular Weight:
432.59
Package Type:
Vial
Product Description:
Latanoprost is the isopropyl ester of 17-phenyl-13,14-dihydro prostaglandin F2alpha (17-phenyl-13,14-dihydro PGF2alpha). It is a prodrug form of the free acid, which is a potent agonist of the FP prostaglandin receptor in the eye. Latanoprost reduces intraocular pressure in glaucoma patients with few side effects.
Purity:
>98% (HPLC)
SMILES:
O[C@@H]1[C@H](C/C=CCCCC(OC(C)C)=O)[C@@H](CC[C@@H](O)CCC2=CC=CC=C2)[C@H](O)C1
Solubility Chemicals:
Soluble in DMSO, methanol or ethanol.
Source / Host:
Synthetic
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
(1) J. Stjernschantz & B. Resul; Drugs Future 17, 691 (1992) | (2) A. Alm, et al.; Ophthalmol. 100, 1312 (1993) | (3) C.B. Camras, et al.; Ophthalmol. 103, 1916 (1996) | (4) E. Linden, et al.; Br. J. Ophthalmol. 81, 370 (1997) | (5) J. Stjernschantz; Invest. Ophthalmol. Vis. Sci. 42, 1134 (2001) (Review) | (6) A. Alm, et al.; Clin Ophthalmol. 8, 1967 (2014) (Review)